Dapsone 25mg NDC 85185-104

NDC codes

FDA NDC Directory

Product NDC (as listed)85185-104Labeler and product segments. Claims need a package NDC.

Product NDC at billing width85185-0104Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
85185-104-01	85185010401	30 TABLET in 1 BOTTLE (85185-104-01)Marketed from May 9, 2016
85185-104-02	85185010402	100 TABLET in 1 BOTTLE (85185-104-02)Marketed from May 9, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dapsone 25mg
Generic name (nonproprietary): dapsone 25mg
Active ingredients: Dapsone — 25 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Solis Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 203887
Marketing start: May 9, 2016
Listing expires: Dec 31, 2027
Other FDA classes: Sulfones (Chemical structure)
Identifiers: Product ID 85185-104_50209cd1-afc6-53f4-e063-6394a90af9cfSPL ID 50209cd1-afc6-53f4-e063-6394a90af9cfSPL set ID 50204029-4c29-5b8d-e063-6394a90af383RxCUI 197557, 197558UNII 8W5C518302UPC 0385185105024
Pharmacologic class: Sulfone

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N485185010401 followed by a unit qualifier and the quantity

Package 85185-0104-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 17, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 203887

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 203887
Product	Strength	Form · route	Labeler	Product NDC
Dapsone 100mg	Dapsone 100 mg/1	TabletOral	Solis Pharmaceuticals Inc.	85185-105
Dapsone	Dapsone 25 mg/1	TabletOral	Golden State Medical Supply, Inc.	60429-495